Clinical Trial Update: Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial update describing treatment with genetically engineered lymphocytes, cyclophosphamide, and aldesleukin in relapsed or refractory Mantle Cell Lymph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent B-cell Non-hodgkin Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• Aldesleukin (interleukin-2)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Genetically Engineered Lymphocytes

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: B-cell Chronic Lymphocytic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 1 | Status: COMPLETED